NZ562221A - Xenotropic murine leukemia virus related virus (XMRV) associated with cancer - Google Patents

Info

Publication number

NZ562221A

NZ562221A NZ562221A NZ56222106A NZ562221A NZ 562221 A NZ562221 A NZ 562221A NZ 562221 A NZ562221 A NZ 562221A NZ 56222106 A NZ56222106 A NZ 56222106A NZ 562221 A NZ562221 A NZ 562221A

Authority

NZ

New Zealand

Prior art keywords

xmrv

virus

seq

nucleic acid

polypeptide

Prior art date

2005-04-07

Links

• Espacenet
• Global Dossier
• Discuss

• 241000101098 Xenotropic MuLV-related virus Species 0.000 title claims description 424
• 206010028980 Neoplasm Diseases 0.000 title abstract description 115
• 201000011510 cancer Diseases 0.000 title description 64
• 238000000034 method Methods 0.000 claims abstract description 151
• 241000700605 Viruses Species 0.000 claims abstract description 150
• 206010060862 Prostate cancer Diseases 0.000 claims abstract description 89
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 79
• 210000002307 prostate Anatomy 0.000 claims abstract description 60
• 239000003795 chemical substances by application Substances 0.000 claims abstract description 54
• 241001529936 Murinae Species 0.000 claims abstract description 15
• 239000003814 drug Substances 0.000 claims abstract description 14
• 230000028993 immune response Effects 0.000 claims abstract description 10
• 208000032839 leukemia Diseases 0.000 claims abstract description 10
• 230000001939 inductive effect Effects 0.000 claims abstract description 9
• 238000004519 manufacturing process Methods 0.000 claims abstract description 7
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 261
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 250
• 229920001184 polypeptide Polymers 0.000 claims description 244
• 150000007523 nucleic acids Chemical group 0.000 claims description 201
• 102100027962 2-5A-dependent ribonuclease Human genes 0.000 claims description 106
• 150000001875 compounds Chemical class 0.000 claims description 77
• 239000012634 fragment Substances 0.000 claims description 75
• 108010000834 2-5A-dependent ribonuclease Proteins 0.000 claims description 70
• 238000009396 hybridization Methods 0.000 claims description 65
• 241000282414 Homo sapiens Species 0.000 claims description 61
• 241000714177 Murine leukemia virus Species 0.000 claims description 55
• 230000000694 effects Effects 0.000 claims description 47
• 101001080057 Homo sapiens 2-5A-dependent ribonuclease Proteins 0.000 claims description 39
• 230000035772 mutation Effects 0.000 claims description 39
• 239000013598 vector Substances 0.000 claims description 39
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 37
• 230000000295 complement effect Effects 0.000 claims description 32
• 230000001177 retroviral effect Effects 0.000 claims description 25
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 23
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 21
• 208000005074 Retroviridae Infections Diseases 0.000 claims description 21
• 239000000427 antigen Substances 0.000 claims description 16
• 108091007433 antigens Proteins 0.000 claims description 16
• 102000036639 antigens Human genes 0.000 claims description 16
• 238000011282 treatment Methods 0.000 claims description 15
• 239000002245 particle Substances 0.000 claims description 14
• 230000001225 therapeutic effect Effects 0.000 claims description 13
• 208000023958 prostate neoplasm Diseases 0.000 claims description 12
• 208000020735 familial prostate carcinoma Diseases 0.000 claims description 11
• 241000713893 Xenotropic murine leukemia virus Species 0.000 claims description 7
• 108700028369 Alleles Proteins 0.000 claims description 6
• 230000002238 attenuated effect Effects 0.000 claims description 4
• 230000002265 prevention Effects 0.000 claims description 3
• 125000003275 alpha amino acid group Chemical group 0.000 claims 7
• 102100028572 Disabled homolog 2 Human genes 0.000 claims 1
• 101710197163 Disabled homolog 2 Proteins 0.000 claims 1
• 102100024233 High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Human genes 0.000 claims 1
• 102100034343 Integrase Human genes 0.000 claims 1
• 101100070104 Mus musculus Hacl1 gene Proteins 0.000 claims 1
• 101710127370 Probable head completion protein 1 Proteins 0.000 claims 1
• 210000004027 cell Anatomy 0.000 description 270
• 102000039446 nucleic acids Human genes 0.000 description 166
• 108020004707 nucleic acids Proteins 0.000 description 166
• 239000000523 sample Substances 0.000 description 125
• 239000002773 nucleotide Substances 0.000 description 95
• 125000003729 nucleotide group Chemical group 0.000 description 92
• 108020004414 DNA Proteins 0.000 description 81
• 210000001519 tissue Anatomy 0.000 description 81
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 76
• 239000013615 primer Substances 0.000 description 67
• 208000015181 infectious disease Diseases 0.000 description 63
• 108090000623 proteins and genes Proteins 0.000 description 59
• 230000003612 virological effect Effects 0.000 description 55
• 238000003752 polymerase chain reaction Methods 0.000 description 54
• 150000001413 amino acids Chemical group 0.000 description 50
• 238000003757 reverse transcription PCR Methods 0.000 description 43
• 230000014509 gene expression Effects 0.000 description 36
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
• 235000018102 proteins Nutrition 0.000 description 34
• 102000004169 proteins and genes Human genes 0.000 description 34
• 239000000203 mixture Substances 0.000 description 33
• 101150077651 VP35 gene Proteins 0.000 description 31
• 201000010099 disease Diseases 0.000 description 30
• 241001430294 unidentified retrovirus Species 0.000 description 30
• 239000002299 complementary DNA Substances 0.000 description 29
• 239000000463 material Substances 0.000 description 29
• 238000004458 analytical method Methods 0.000 description 28
• 238000003556 assay Methods 0.000 description 27
• 238000002493 microarray Methods 0.000 description 26
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 25
• 102100034349 Integrase Human genes 0.000 description 24
• 230000000875 corresponding effect Effects 0.000 description 23
• 235000001014 amino acid Nutrition 0.000 description 22
• 241001663880 Gammaretrovirus Species 0.000 description 21
• 230000004927 fusion Effects 0.000 description 21
• 239000013604 expression vector Substances 0.000 description 20
• 108091034117 Oligonucleotide Proteins 0.000 description 19
• 238000003364 immunohistochemistry Methods 0.000 description 19
• 239000000126 substance Substances 0.000 description 19
• 230000004071 biological effect Effects 0.000 description 18
• 230000006870 function Effects 0.000 description 18
• 241000699666 Mus <mouse, genus> Species 0.000 description 17
• 230000002441 reversible effect Effects 0.000 description 17
• 238000012216 screening Methods 0.000 description 17
• 241000713813 Gibbon ape leukemia virus Species 0.000 description 16
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 16
• 239000003153 chemical reaction reagent Substances 0.000 description 16
• 238000001514 detection method Methods 0.000 description 16
• 230000010076 replication Effects 0.000 description 16
• 238000012360 testing method Methods 0.000 description 16
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
• 229910001868 water Inorganic materials 0.000 description 16
• 101710177291 Gag polyprotein Proteins 0.000 description 15
• 108090001074 Nucleocapsid Proteins Proteins 0.000 description 15
• 239000000872 buffer Substances 0.000 description 15
• 244000052769 pathogen Species 0.000 description 15
• 239000006228 supernatant Substances 0.000 description 15
• 101800000789 Protease-polymerase p70 Proteins 0.000 description 14
• 101800000786 Protease-polymerase p76 Proteins 0.000 description 14
• 108091081024 Start codon Proteins 0.000 description 14
• 239000000047 product Substances 0.000 description 14
• 230000001105 regulatory effect Effects 0.000 description 14
• 239000000243 solution Substances 0.000 description 14
• 241000714165 Feline leukemia virus Species 0.000 description 13
• 101710125418 Major capsid protein Proteins 0.000 description 13
• 238000006243 chemical reaction Methods 0.000 description 13
• 238000001727 in vivo Methods 0.000 description 13
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 12
• 102000014150 Interferons Human genes 0.000 description 12
• 108010050904 Interferons Proteins 0.000 description 12
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
• 241000881678 Koala retrovirus Species 0.000 description 12
• 108700026244 Open Reading Frames Proteins 0.000 description 12
• 210000000234 capsid Anatomy 0.000 description 12
• 230000010354 integration Effects 0.000 description 12
• 210000004940 nucleus Anatomy 0.000 description 12
• 239000002987 primer (paints) Substances 0.000 description 12
• 102000005962 receptors Human genes 0.000 description 12
• 108020003175 receptors Proteins 0.000 description 12
• 238000012163 sequencing technique Methods 0.000 description 12
• 210000002536 stromal cell Anatomy 0.000 description 12
• 238000006467 substitution reaction Methods 0.000 description 12
• 230000003321 amplification Effects 0.000 description 11
• 238000012217 deletion Methods 0.000 description 11
• 230000037430 deletion Effects 0.000 description 11
• 108010078428 env Gene Products Proteins 0.000 description 11
• -1 for 30 example Proteins 0.000 description 11
• 238000002372 labelling Methods 0.000 description 11
• 238000003199 nucleic acid amplification method Methods 0.000 description 11
• 238000002360 preparation method Methods 0.000 description 11
• 108020004705 Codon Proteins 0.000 description 10
• 108020004511 Recombinant DNA Proteins 0.000 description 10
• 239000002253 acid Substances 0.000 description 10
• 230000001413 cellular effect Effects 0.000 description 10
• 238000000338 in vitro Methods 0.000 description 10
• 230000001965 increasing effect Effects 0.000 description 10
• 230000002458 infectious effect Effects 0.000 description 10
• 230000014616 translation Effects 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 231100000504 carcinogenesis Toxicity 0.000 description 9
• 239000012707 chemical precursor Substances 0.000 description 9
• 229940079322 interferon Drugs 0.000 description 9
• 230000003902 lesion Effects 0.000 description 9
• 239000003550 marker Substances 0.000 description 9
• 108020004999 messenger RNA Proteins 0.000 description 9
• 239000013612 plasmid Substances 0.000 description 9
• 210000000064 prostate epithelial cell Anatomy 0.000 description 9
• 241000894007 species Species 0.000 description 9
• 238000013519 translation Methods 0.000 description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
• 239000012981 Hank's balanced salt solution Substances 0.000 description 8
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 8
• 108091027544 Subgenomic mRNA Proteins 0.000 description 8
• 230000000840 anti-viral effect Effects 0.000 description 8
• 238000010367 cloning Methods 0.000 description 8
• 238000010166 immunofluorescence Methods 0.000 description 8
• 238000007901 in situ hybridization Methods 0.000 description 8
• 238000005304 joining Methods 0.000 description 8
• 239000002853 nucleic acid probe Substances 0.000 description 8
• 239000012188 paraffin wax Substances 0.000 description 8
• 239000013641 positive control Substances 0.000 description 8
• 238000011471 prostatectomy Methods 0.000 description 8
• 238000002976 reverse transcriptase assay Methods 0.000 description 8
• 238000005406 washing Methods 0.000 description 8
• 208000005623 Carcinogenesis Diseases 0.000 description 7
• 108010053770 Deoxyribonucleases Proteins 0.000 description 7
• 102000016911 Deoxyribonucleases Human genes 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 238000000636 Northern blotting Methods 0.000 description 7
• 241000283984 Rodentia Species 0.000 description 7
• 238000002105 Southern blotting Methods 0.000 description 7
• 239000011543 agarose gel Substances 0.000 description 7
• 230000036952 cancer formation Effects 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 229940088598 enzyme Drugs 0.000 description 7
• 239000012091 fetal bovine serum Substances 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 108700010759 gag-pro-pol Proteins 0.000 description 7
• 101150061559 gag-pro-pol gene Proteins 0.000 description 7
• 239000000499 gel Substances 0.000 description 7
• 210000004408 hybridoma Anatomy 0.000 description 7
• 238000003780 insertion Methods 0.000 description 7
• 230000037431 insertion Effects 0.000 description 7
• 239000013642 negative control Substances 0.000 description 7
• 238000003259 recombinant expression Methods 0.000 description 7
• 210000000952 spleen Anatomy 0.000 description 7
• 208000024891 symptom Diseases 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 201000009030 Carcinoma Diseases 0.000 description 6
• 101710118026 Gag-Pro-Pol polyprotein Proteins 0.000 description 6
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
• 108060003951 Immunoglobulin Proteins 0.000 description 6
• 206010061218 Inflammation Diseases 0.000 description 6
• 241000180709 Murine type C retrovirus Species 0.000 description 6
• 108700020796 Oncogene Proteins 0.000 description 6
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
• 206010041067 Small cell lung cancer Diseases 0.000 description 6
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
• 108020005202 Viral DNA Proteins 0.000 description 6
• 238000000246 agarose gel electrophoresis Methods 0.000 description 6
• 238000010171 animal model Methods 0.000 description 6
• 239000011230 binding agent Substances 0.000 description 6
• 239000012620 biological material Substances 0.000 description 6
• 238000004113 cell culture Methods 0.000 description 6
• 210000000805 cytoplasm Anatomy 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• 230000029087 digestion Effects 0.000 description 6
• 239000000284 extract Substances 0.000 description 6
• 102000037865 fusion proteins Human genes 0.000 description 6
• 108020001507 fusion proteins Proteins 0.000 description 6
• 238000003205 genotyping method Methods 0.000 description 6
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 210000005260 human cell Anatomy 0.000 description 6
• 102000018358 immunoglobulin Human genes 0.000 description 6
• 230000004054 inflammatory process Effects 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 239000003068 molecular probe Substances 0.000 description 6
• 230000007935 neutral effect Effects 0.000 description 6
• 239000008194 pharmaceutical composition Substances 0.000 description 6
• 208000000587 small cell lung carcinoma Diseases 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 238000010186 staining Methods 0.000 description 6
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 241000283707 Capra Species 0.000 description 5
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
• 238000000018 DNA microarray Methods 0.000 description 5
• 239000003298 DNA probe Substances 0.000 description 5
• 108010067770 Endopeptidase K Proteins 0.000 description 5
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 5
• 102100034353 Integrase Human genes 0.000 description 5
• 102000011782 Keratins Human genes 0.000 description 5
• 108010076876 Keratins Proteins 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• 206010071019 Prostatic dysplasia Diseases 0.000 description 5
• 108020004566 Transfer RNA Proteins 0.000 description 5
• 108020000999 Viral RNA Proteins 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 230000004075 alteration Effects 0.000 description 5
• 230000000692 anti-sense effect Effects 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 235000011089 carbon dioxide Nutrition 0.000 description 5
• 210000000349 chromosome Anatomy 0.000 description 5
• 210000002919 epithelial cell Anatomy 0.000 description 5
• 210000002950 fibroblast Anatomy 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 239000012120 mounting media Substances 0.000 description 5
• 238000013081 phylogenetic analysis Methods 0.000 description 5
• 230000002062 proliferating effect Effects 0.000 description 5
• 210000005267 prostate cell Anatomy 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 238000007423 screening assay Methods 0.000 description 5
• 150000003384 small molecules Chemical class 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• 238000013518 transcription Methods 0.000 description 5
• 230000035897 transcription Effects 0.000 description 5
• 230000029812 viral genome replication Effects 0.000 description 5
• 102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 4
• 108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 4
• 206010003694 Atrophy Diseases 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 108010070675 Glutathione transferase Proteins 0.000 description 4
• 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• 108091005804 Peptidases Proteins 0.000 description 4
• 108010076504 Protein Sorting Signals Proteins 0.000 description 4
• 108010083644 Ribonucleases Proteins 0.000 description 4
• 102000006382 Ribonucleases Human genes 0.000 description 4
• 101500019086 Ustilago maydis P6 virus KP6 killer toxin subunit alpha Proteins 0.000 description 4
• 108010004696 Xenotropic and Polytropic Retrovirus Receptor Proteins 0.000 description 4
• 102100036974 Xenotropic and polytropic retrovirus receptor 1 Human genes 0.000 description 4
• SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 4
• 239000005557 antagonist Substances 0.000 description 4
• 238000003491 array Methods 0.000 description 4
• 230000037444 atrophy Effects 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• 239000006285 cell suspension Substances 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 238000011109 contamination Methods 0.000 description 4
• 239000013068 control sample Substances 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 231100000517 death Toxicity 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
• 229960005542 ethidium bromide Drugs 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 238000000605 extraction Methods 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 239000003102 growth factor Substances 0.000 description 4
• 239000001963 growth medium Substances 0.000 description 4
• 230000002163 immunogen Effects 0.000 description 4
• 238000011065 in-situ storage Methods 0.000 description 4
• 230000000415 inactivating effect Effects 0.000 description 4
• 230000002452 interceptive effect Effects 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 238000002966 oligonucleotide array Methods 0.000 description 4
• 230000007170 pathology Effects 0.000 description 4
• 230000002093 peripheral effect Effects 0.000 description 4
• 102000040430 polynucleotide Human genes 0.000 description 4
• 108091033319 polynucleotide Proteins 0.000 description 4
• 239000002157 polynucleotide Substances 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 239000011541 reaction mixture Substances 0.000 description 4
• 238000011084 recovery Methods 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 230000000699 topical effect Effects 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 230000009385 viral infection Effects 0.000 description 4
• 238000001262 western blot Methods 0.000 description 4
• 108020004463 18S ribosomal RNA Proteins 0.000 description 3
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
• 101710132601 Capsid protein Proteins 0.000 description 3
• 108010001857 Cell Surface Receptors Proteins 0.000 description 3
• 102000000844 Cell Surface Receptors Human genes 0.000 description 3
• 102100037623 Centromere protein V Human genes 0.000 description 3
• 102000053602 DNA Human genes 0.000 description 3
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
• 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 3
• 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 102000003886 Glycoproteins Human genes 0.000 description 3
• 108090000288 Glycoproteins Proteins 0.000 description 3
• 241001502974 Human gammaherpesvirus 8 Species 0.000 description 3
• 108010061833 Integrases Proteins 0.000 description 3
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
• 101710189818 Non-structural protein 2a Proteins 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 238000012408 PCR amplification Methods 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• 101710151911 Phosphoprotein p30 Proteins 0.000 description 3
• 108010076039 Polyproteins Proteins 0.000 description 3
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
• 239000004365 Protease Substances 0.000 description 3
• 238000002123 RNA extraction Methods 0.000 description 3
• 239000013614 RNA sample Substances 0.000 description 3
• 238000010240 RT-PCR analysis Methods 0.000 description 3
• 108091027981 Response element Proteins 0.000 description 3
• 238000012300 Sequence Analysis Methods 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 108010067390 Viral Proteins Proteins 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 241001092419 Xenotropic MuLV-related virus VP35 Species 0.000 description 3
• 238000007792 addition Methods 0.000 description 3
• 230000032683 aging Effects 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 238000000137 annealing Methods 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 239000012472 biological sample Substances 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 239000004568 cement Substances 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 108091036078 conserved sequence Proteins 0.000 description 3
• 238000012937 correction Methods 0.000 description 3
• 230000000120 cytopathologic effect Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 108700004025 env Genes Proteins 0.000 description 3
• 230000007613 environmental effect Effects 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
• 108700004026 gag Genes Proteins 0.000 description 3
• 101150098622 gag gene Proteins 0.000 description 3
• 238000001502 gel electrophoresis Methods 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 239000003862 glucocorticoid Substances 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
• 230000003053 immunization Effects 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 238000007834 ligase chain reaction Methods 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 238000010208 microarray analysis Methods 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 238000012544 monitoring process Methods 0.000 description 3
• 238000002887 multiple sequence alignment Methods 0.000 description 3
• 238000007857 nested PCR Methods 0.000 description 3
• 230000003287 optical effect Effects 0.000 description 3
• 238000004806 packaging method and process Methods 0.000 description 3
• 239000000816 peptidomimetic Substances 0.000 description 3
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
• 102000013415 peroxidase activity proteins Human genes 0.000 description 3
• 108040007629 peroxidase activity proteins Proteins 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• 230000008488 polyadenylation Effects 0.000 description 3
• 102000054765 polymorphisms of proteins Human genes 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 230000001566 pro-viral effect Effects 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 210000001236 prokaryotic cell Anatomy 0.000 description 3
• 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 3
• 238000010839 reverse transcription Methods 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 238000001308 synthesis method Methods 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 239000003104 tissue culture media Substances 0.000 description 3
• 238000012800 visualization Methods 0.000 description 3
• 239000000080 wetting agent Substances 0.000 description 3
• 239000008096 xylene Substances 0.000 description 3
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
• 108020005096 28S Ribosomal RNA Proteins 0.000 description 2
• 239000012110 Alexa Fluor 594 Substances 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 108020004635 Complementary DNA Proteins 0.000 description 2
• 238000000116 DAPI staining Methods 0.000 description 2
• 108020003215 DNA Probes Proteins 0.000 description 2
• 239000003155 DNA primer Substances 0.000 description 2
• AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
• 208000036566 Erythroleukaemia Diseases 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
• 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 2
• 101710194460 Growth/differentiation factor 15 Proteins 0.000 description 2
• 101710082439 Hemagglutinin A Proteins 0.000 description 2
• 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 101001094647 Homo sapiens Serum paraoxonase/arylesterase 1 Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 102000003960 Ligases Human genes 0.000 description 2
• 108090000364 Ligases Proteins 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 241000772415 Neovison vison Species 0.000 description 2
• 108091092724 Noncoding DNA Proteins 0.000 description 2
• 239000004677 Nylon Substances 0.000 description 2
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
• 102000043276 Oncogene Human genes 0.000 description 2
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
• 101710120319 Photosystem I reaction center subunit IV Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 241000712907 Retroviridae Species 0.000 description 2
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• 102100035476 Serum paraoxonase/arylesterase 1 Human genes 0.000 description 2
• 208000019802 Sexually transmitted disease Diseases 0.000 description 2
• 108091027967 Small hairpin RNA Proteins 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 241000713880 Spleen focus-forming virus Species 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 108010006785 Taq Polymerase Proteins 0.000 description 2
• 101150026858 VP30 gene Proteins 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
• 208000021841 acute erythroid leukemia Diseases 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 238000012197 amplification kit Methods 0.000 description 2
• 239000003708 ampul Substances 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 239000012752 auxiliary agent Substances 0.000 description 2
• 210000003050 axon Anatomy 0.000 description 2
• 230000037429 base substitution Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 238000010804 cDNA synthesis Methods 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 230000005860 defense response to virus Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000004925 denaturation Methods 0.000 description 2
• 230000036425 denaturation Effects 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 238000007876 drug discovery Methods 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 101150030339 env gene Proteins 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 238000012869 ethanol precipitation Methods 0.000 description 2
• 238000000799 fluorescence microscopy Methods 0.000 description 2
• 239000012737 fresh medium Substances 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 210000004907 gland Anatomy 0.000 description 2
• 239000005090 green fluorescent protein Substances 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
• 230000003054 hormonal effect Effects 0.000 description 2
• 102000047486 human GAPDH Human genes 0.000 description 2
• 210000003917 human chromosome Anatomy 0.000 description 2
• 238000002169 hydrotherapy Methods 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 238000002991 immunohistochemical analysis Methods 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 238000005462 in vivo assay Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 229940047124 interferons Drugs 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 238000000386 microscopy Methods 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 229930014626 natural product Natural products 0.000 description 2
• 229920001778 nylon Polymers 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000002751 oligonucleotide probe Substances 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 239000013610 patient sample Substances 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 108700004029 pol Genes Proteins 0.000 description 2
• 101150088264 pol gene Proteins 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 201000001514 prostate carcinoma Diseases 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
• LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
• 239000012857 radioactive material Substances 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 238000005215 recombination Methods 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 230000003362 replicative effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• 239000012266 salt solution Substances 0.000 description 2
• 239000004055 small Interfering RNA Substances 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000001131 transforming effect Effects 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 229920002554 vinyl polymer Polymers 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• 230000009278 visceral effect Effects 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• 229960002555 zidovudine Drugs 0.000 description 2
• 102100036413 2',5'-phosphodiesterase 12 Human genes 0.000 description 1
• 101710164011 2',5'-phosphodiesterase 12 Proteins 0.000 description 1
• MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
• 108020005345 3' Untranslated Regions Proteins 0.000 description 1
• VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
• 108020003589 5' Untranslated Regions Proteins 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• 101710152894 ATP-binding cassette sub-family E member 1 Proteins 0.000 description 1
• 102100020969 ATP-binding cassette sub-family E member 1 Human genes 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 241000710929 Alphavirus Species 0.000 description 1
• 108050005273 Amino acid transporters Proteins 0.000 description 1
• 102000034263 Amino acid transporters Human genes 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 108091093088 Amplicon Proteins 0.000 description 1
• 229920000856 Amylose Polymers 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
• 101100049486 Autographa californica nuclear polyhedrosis virus VP80 gene Proteins 0.000 description 1
• 241001213911 Avian retroviruses Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 102000052609 BRCA2 Human genes 0.000 description 1
• 108700020462 BRCA2 Proteins 0.000 description 1
• 101001124039 Banna virus (strain Indonesia/JKT-6423/1980) Non-structural protein 4 Proteins 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101150008921 Brca2 gene Proteins 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
• 101100535275 Caenorhabditis elegans syg-1 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
• 102000003952 Caspase 3 Human genes 0.000 description 1
• 108090000397 Caspase 3 Proteins 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 108020004394 Complementary RNA Proteins 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 241000709687 Coxsackievirus Species 0.000 description 1
• 102000018832 Cytochromes Human genes 0.000 description 1
• 108010052832 Cytochromes Proteins 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 102000012410 DNA Ligases Human genes 0.000 description 1
• 108010061982 DNA Ligases Proteins 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 102100035619 DNA-(apurinic or apyrimidinic site) lyase Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 101710121417 Envelope glycoprotein Proteins 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241001663878 Epsilonretrovirus Species 0.000 description 1
• 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 1
• 208000004729 Feline Leukemia Diseases 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 238000000729 Fisher's exact test Methods 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 102100030943 Glutathione S-transferase P Human genes 0.000 description 1
• 101710166825 Glyco-Gag protein Proteins 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
• 101000933041 His1 virus (isolate Australia/Victoria) Major capsid protein Proteins 0.000 description 1
• 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
• 101001137256 Homo sapiens DNA-(apurinic or apyrimidinic site) lyase Proteins 0.000 description 1
• 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 description 1
• 101001134216 Homo sapiens Macrophage scavenger receptor types I and II Proteins 0.000 description 1
• 101100198352 Homo sapiens RNASEL gene Proteins 0.000 description 1
• 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
• 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 241000701806 Human papillomavirus Species 0.000 description 1
• 241000829111 Human polyomavirus 1 Species 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010058683 Immobilized Proteins Proteins 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 102100040443 Keratin, type I cytoskeletal 15 Human genes 0.000 description 1
• 108010066330 Keratin-15 Proteins 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 101800000316 Movement protein Proteins 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101100013786 Mus musculus Gapdh gene Proteins 0.000 description 1
• 101000819572 Mus musculus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 238000011785 NMRI mouse Methods 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 101100123117 Nicotiana plumbaginifolia MSR-1 gene Proteins 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 101000957149 Paramecium bursaria Chlorella virus 1 Major capsid protein Proteins 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 241001520316 Phascolarctidae Species 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 241000709664 Picornaviridae Species 0.000 description 1
• 108090000316 Pitrilysin Proteins 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 101710160829 Poly(A) polymerase catalytic subunit Proteins 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 1
• 101710180316 Protease 2 Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 108020004518 RNA Probes Proteins 0.000 description 1
• 239000003391 RNA probe Substances 0.000 description 1
• 101000694612 Rattus norvegicus Membrane primary amine oxidase Proteins 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 241001068263 Replication competent viruses Species 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 108091081400 Subtelomere Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 101710192266 Tegument protein VP22 Proteins 0.000 description 1
• 108020005038 Terminator Codon Proteins 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 102000002689 Toll-like receptor Human genes 0.000 description 1
• 108020000411 Toll-like receptor Proteins 0.000 description 1
• 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
• 101710114283 Translation initiation factor RLI1 Proteins 0.000 description 1
• 239000007984 Tris EDTA buffer Substances 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
• 101150010086 VP24 gene Proteins 0.000 description 1
• 101150036892 VP40 gene Proteins 0.000 description 1
• 101800003447 VP53 Proteins 0.000 description 1
• 101800000864 VP58 Proteins 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 206010058874 Viraemia Diseases 0.000 description 1
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
• 108700005077 Viral Genes Proteins 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 101001128925 Zea mays 9-cis-epoxycarotenoid dioxygenase 1, chloroplastic Proteins 0.000 description 1
• 101100023962 Zea mays VP15 gene Proteins 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 150000001408 amides Chemical group 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 230000003172 anti-dna Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 150000003938 benzyl alcohols Chemical class 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
• 235000010633 broth Nutrition 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 125000000837 carbohydrate group Chemical group 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 108091092356 cellular DNA Proteins 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 229940125773 compound 10 Drugs 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000000287 crude extract Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 238000012303 cytoplasmic staining Methods 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
• NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000002222 downregulating effect Effects 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 230000001973 epigenetic effect Effects 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 230000008826 genomic mutation Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 238000012188 high-throughput screening assay Methods 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 238000010231 histologic analysis Methods 0.000 description 1
• 230000002962 histologic effect Effects 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 238000013383 initial experiment Methods 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 210000005007 innate immune system Anatomy 0.000 description 1
• 238000002743 insertional mutagenesis Methods 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 239000000865 liniment Substances 0.000 description 1
• 125000003473 lipid group Chemical group 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 238000007403 mPCR Methods 0.000 description 1
• 101710121537 mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 238000000329 molecular dynamics simulation Methods 0.000 description 1
• 230000004784 molecular pathogenesis Effects 0.000 description 1
• 239000002808 molecular sieve Substances 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 231100000219 mutagenic Toxicity 0.000 description 1
• 239000003471 mutagenic agent Substances 0.000 description 1
• 231100000707 mutagenic chemical Toxicity 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 238000011392 neighbor-joining method Methods 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 230000006508 oncogene activation Effects 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 230000004792 oxidative damage Effects 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229940056360 penicillin g Drugs 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 239000002304 perfume Substances 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 238000005222 photoaffinity labeling Methods 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 230000026447 protein localization Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 239000012264 purified product Substances 0.000 description 1
• 235000008160 pyridoxine Nutrition 0.000 description 1
• 239000011677 pyridoxine Substances 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 230000000171 quenching effect Effects 0.000 description 1
• 238000011472 radical prostatectomy Methods 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000011506 response to oxidative stress Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 229940064914 retrovir Drugs 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
• 238000010079 rubber tapping Methods 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 238000005204 segregation Methods 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 230000005582 sexual transmission Effects 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 238000002791 soaking Methods 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000006104 solid solution Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 238000003153 stable transfection Methods 0.000 description 1
• 239000008227 sterile water for injection Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000012916 structural analysis Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 238000005382 thermal cycling Methods 0.000 description 1
• 238000006257 total synthesis reaction Methods 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 230000010415 tropism Effects 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 230000006648 viral gene expression Effects 0.000 description 1
• 244000052613 viral pathogen Species 0.000 description 1
• 229940011671 vitamin b6 Drugs 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 150000003738 xylenes Chemical class 0.000 description 1
• 238000001086 yeast two-hybrid system Methods 0.000 description 1